The diagnostic testing ecosystem is broken, hindering the progress of Precision Medicine in 2019, according to Diaceutics’ just published Pharma Precision Medicine Readiness Report 2019. In this latest annual assessment of the state of Precision Medicine, Diaceutics calls on the Precision Medicine community to rethink the relationship between testing and treatment, and end the “siloed thinking that is denying patients access to the right tests and better treatments.”
In the Report, Diaceutics draws on its experience with more than 500 therapy/diagnostic projects and the insights derived from real-world data to depict the toll that this fragmented commercial approach is having on patients. The Report reveals the challenges and strategic mistakes that continue to impair the onward march of Precision Medicine, including those involving the diagnostic supply chain, relations between the Pharma and Lab industries, suboptimal investment in biomarker/therapy combinations, and core hurdles to optimal precision testing facing Pharma commercial teams.
Additionally, the Report
- Describes Diaceutics’ solution to this broken diagnostic testing ecosystem through the global harmonization of clinical lab tests,
- Identifies the megatrends characterizing Precision Medicine in 2019, and
- Predicts the drivers and disruptors that will shape Precision Medicine in the next 3 to 5 years.
Download the full Diaceutics Pharma Precision Medicine Readiness Report 2019 here to get the full story on Precision Medicine!
